The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 dose escalation and cohort expansion study evaluating safety, PK, PD and clinical activity of STC-15, a METTL-3 inhibitor, in patients with advanced malignancies.
 
Justin C Moser
Honoraria - Caris Life Sciences; Daiichi Sankyo/Lilly; TGen
Consulting or Advisory Role - Adagene; Amunix; Boxer Capitol; Bristol Myers Squibb Foundation; Genome Insight; Imaging Endpoints; Incyte; IQvia; Novotech; Oberland Capital; Red Arrow Therapeutics; Thirona Biosciences; Werewolf Therapeutics (Inst)
Speakers' Bureau - Caris Life Sciences; Castle Biosciences; Immunocore
Research Funding - Adaptimmune (Inst); Agenus (Inst); Alpine Immune Sciences (Inst); Amgen (Inst); BioEclipse Therapeutics (Inst); Fate Therapeutics (Inst); Fujifilm (Inst); Genentech (Inst); IDEAYA Biosciences (Inst); ImmuneSensor Therapeutics (Inst); Iovance Biotherapeutics (Inst); Istari Oncology (Inst); Nektar (Inst); Novocure (Inst); Repertoire Immune Medicines (Inst); Rubius Therapeutics (Inst); Senhwa Biosciences (Inst); Simcha Therapeutics (Inst); Storm Therapeutics (Inst); Synthorx (Inst); T-Scan Therapeutics (Inst); Trishula Therapeutics (Inst); University of Arizona (Inst); Werewolf Therapeutics (Inst); Y-mAbs Therapeutics (Inst)
Other Relationship - Caris Life Sciences
 
Kyriakos P. Papadopoulos
Consulting or Advisory Role - Basilea; Bicycle Therapeutics; Turning Point Therapeutics
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Biontech (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); F-star (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Kezar Life Sciences (Inst); Lilly (Inst); Linnaeus Therapeutics (Inst); MabSpace Biosciences (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Regeneron (Inst); Revolution Medicines (Inst); Sensei Biotherapeutics (Inst); Storm Therapeutics (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Treadwell Therapeutics (Inst)
 
Jordi Rodon Ahnert
Consulting or Advisory Role - AADi; Alynlam Pharmaceuticals; Avoro Capital Advisors; Boxer Capital; Chinese University of Hong Kong; Clarion Healthcare; Columbus Venture Partners; Cullgen; Debiopharm Group; Ellipses Pharma; Envision Pharma Group; Incyte; iOnctura; Macrogenics; Merus; Monte Rosa Therapeutics; Oncology One; Pfizer; Sardona Therapeutics; Tang Advisors; Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social
Research Funding - AADi (Inst); Amgen (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Cellestia Biotech (Inst); Curis (Inst); CytomX Therapeutics (Inst); Deciphera (Inst); Fore Biotherapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Hummingbird (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Kelun (Inst); Linnaeus Therapeutics (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Nuvation Bio (Inst); Pfizer (Inst); Roche (Inst); Spectrum Pharmaceuticals (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Takeda/Millennium (Inst); Tango Therapeutics (Inst); Vall d'Hebron Institute of Oncology/Cancer Core Europe (Inst); Yingli Pharma (Inst)
Travel, Accommodations, Expenses - ESMO; Loxo
Other Relationship - Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social
 
Yaara Ofir-Rosenfeld
Employment - Storm Therapeutics
Stock and Other Ownership Interests - Mission Therapeutics
Patents, Royalties, Other Intellectual Property - I am named as an inventor on patents from Mission Therapeutics and Storm Therapeutics; Inventor on patents from Cancer Research UK (I)
 
Josefin-Beate Holz
Stock and Other Ownership Interests - Calypso Medical; Gilead Sciences; Storm Therapeutics
Consulting or Advisory Role - Calypso Medical; Prokarium; Storm Therapeutics; Synklino; Targed